Loading...
Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors
PURPOSE: AUY922 is a potent non-geldanamycin inhibitor of heat-shock protein 90. This study was carried out in Japanese patients to determine the maximum tolerated dose (MTD), and to characterize safety, tolerability and pharmacokinetics of single-agent AUY922. METHODS: Japanese patients with advanc...
Na minha lista:
Main Authors: | , , , , , , , , , |
---|---|
Format: | Artigo |
Sprog: | Inglês |
Udgivet: |
Springer Berlin Heidelberg
2014
|
Fag: | |
Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4143601/ https://ncbi.nlm.nih.gov/pubmed/25059319 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-014-2521-x |
Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|